21-hydroxylase deficiency risk factors

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
21-hydroxylase deficiency risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 21-hydroxylase deficiency risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 21-hydroxylase deficiency risk factors
CDC on 21-hydroxylase deficiency risk factors
21-hydroxylase deficiency risk factors in the news
Blogs on 21-hydroxylase deficiency risk factors
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Risk calculators and risk factors for 21-hydroxylase deficiency risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

The most potent risk factor in the development of 21-hydroxylase deficient congenital adrenal hyperplasia is mutations in the CYP21A2 gene.

Risk Factors

Mutations in the CYP21A2 gene cause 21-hydroxylase deficient congenital adrenal hyperplasia.